HS387

Phase 1Small molecule

ZZhejiang Hisun Pharmaceutical Co. Ltd.

HS387 is one of 50 small molecule programs targeting Advanced Solid Tumors. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Solid TumorsRecruiting

Advanced Solid TumorsPhase 1

Recruiting

Competition

Competitive Landscape

311 competitors in Advanced Solid Tumors

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 2

25 2

Opdivo

Bristol-Myers Squibb

Phase 2

19 3

Paraplatin

AAvyxa

Phase 2

32 4

Tecentriq

Roche

Phase 2

11 5

Beyfortus

BeiGene

Phase 2

10 6

Taxotere

AAvyxa

Phase 2

23 7

Yervoy

Bristol-Myers Squibb

Phase 2

6 8

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

19 9

Braftovi

Pfizer

Phase 2

4 10

Erbitux

IImclone

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Advanced Solid Tumors

NCT07092748

Clinical

Trials by Indication[1]

Advanced Solid Tumors1 trial

A Phase Ia/ Ib Study of HS387 in Subjects With Advanced Solid Tumors

Recruiting·ZZhejiang Hisun Pharmaceutical Co. Ltd.·Phase 1·NCT07092748·110 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HS387. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HS387 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HS387. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zhejiang Hisun Pharmaceutical Co. Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: ZZhejiang Hisun Pharmaceutical Co. Ltd.

HS387

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Advanced Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News